



Molecular Diagnostics Requisition

FIRST NAME	LAST NAME				
55 #			MIDDLE INITIA	L CLINIC INFORMATION	
	D.O.B.		SEX	RACE	
2222			M F		2
ADDRESS	CITY		STATE	ZIP	PHONE
BILLING: MEDICARE MEDIC	CAID PRIVATE	☐ SELF PAY	CLIENT BILL	□ WC/AUTO	(DATE OF INJUR
CD-10 DIAGNOSIS CODES: Additional document	s supporting medical necessity ma	ay be attached.			
(2)	(3)	(4)		(5)	(6)
ROVIDER NAME (PRINT)			PROVIDER SIG	NATURE	
(X		
COLLECTOR NAME (please print)		DATE COLLECTE		TIME COLLECTED	FASTING ☐ Yes ☐ No
UBE TYPE & COUNT ☐ Dry Buccal Swab: ☐ EDTA:	☐ Mouthwash:		SPECIMEN STO		SPECIMEN SHIPPING:
Cell-Free DNA BCT: Saliva Colle		al Swab:	☐ Room ten		☐ Room temperature ☐ Cooling/Ice Pack
10LECULAR DIAGNOSTIC TESTIN 1 Hereditary Cancer Risk Assessment (E S BMPR I A, BRCA I, BRCA 2, BRIP I, CDH I, CDK 4, C RAD 5 I D, RET, SMAD 4, STK I I, PT 5 3, VHL 1 Personal Breast-Ovarian Cancer ONLY (RAD 5 0, RAD 5 I D, RET, SMAD 4, VHL	SC MW) — APC, ATM, BARDI, CDKN2A, CHEK2, EPCAM, FANCC,		MW = Mouthwa E11A, MSH2, MSH	16, NBN, NF1, NTRK1, PALB2, P	tion NS = Nasopharyngeal Swab MS2, PTCH1, PTEN, RAD50, RAD51C,
Respiratory Pathogen Panel: (NS) - V Influenza A, Influenza A/H1, Influenza A/H1-2009, Chlamydophila pneumoniae, Mycoplasma pneumo	, Influenza A/H3, Influenza B, Parainf				
ANKKI/DRD2, APOE, COMT, CYPs: IA2, 2B6, 2C 2D6 (Copy Number), 3A4, 3A5, DPYD, Factor II, Leiden, HCP5, MTHFR, OPRMI, SLCOIBI, TPMT VKORCI Non-Invasive Prenatal Test (The DISCOVER™ prenatal test is validated for single	Factor V CYPs: 1A2, 2C T, UGT2B15, □ psych/ADHE ANKKI/DRD2, CYPs: 1A2, 2C CD)	II, FactorV Leiden, MTHFR 19, 2C19, 2D6, 3A4, 3A5, D , COMT, MTHFR, and 19, 2C19, 2D6, 3A4, 3A5	R, SLCOIBI,VKORC	CYPs: IA2, 2B6 ☐ cancer COMT, DPYD, T	l and 5, 2C9, 2C19, 2D6, 3A4, 3A5 TPMT, MTHFR, OPRMI, and 3, 2C9, 2D6, 3A4, 3A5
		tational age of at least 10	weeks 0 days, as	estimated by last menstrual per	iod, crown rump length, or other appropr
nethod (equivalent to 8 weeks fetal age as determine	ned by date of conception).		, ,	,	iod, crown rump length, or other appropn
nethod (equivalent to 8 weeks fetal age as determine thoose Either Test (NIPT or NIPT Plus) and All Op	ned by date of conception). ptions That Apply	Test Indications (Choose at least one):		Clinical Information	
nethod (equivalent to 8 weeks fetal age as determing hoose Either Test (NIPT or NIPT Plus) and All Operated Test (chromosomes 21, 18, 13)	ned by date of conception). ptions That Apply Prenatal Plus Test chromosomes 21, 18, 13)	Test Indications		Clinical Information SESTATIONAL AGE: WKS / DA	iod, crown rump length, or other appropri
nethod (equivalent to 8 weeks fetal age as determine hoose Either Test (NIPT or NIPT Plus) and All Operatal Test (chromosomes 21, 18, 13)	ptions That Apply Prenatal Plus Test chromosomes 21, 18, 13) Singleton	Test Indications (Choose at least one):	nal Age	Clinical Information	
choose Either Test (NIPT or NIPT Plus) and All Operated Test (chromosomes 21, 18, 13) Singleton Additional option: Presence of Y Presence of Y Microd	ptions That Apply Prenatal Plus Test chromosomes 21, 18, 13) Singleton I options: leletions	Test Indications (Choose at least one): Advanced Materr Positive Serum So Abnormal Ultraso	nal Age	Clinical Information SESTATIONAL AGE: WKS / DO DATING METHOD: LMP CRL	
Chromosome aneuploidies Chromosome aneuploidies Chromosome Chr	ptions That Apply Prenatal Plus Test chromosomes 21, 18, 13) Singleton I options: leletions leletion, 4p- (Wolf-Hirschhorn), i-du-chat), 15q11.2 deletion (Prader-	Test Indications (Choose at least one): Advanced Matern Positive Serum So Abnormal Ultrass Hx suggestive of risk for the specif	nal Age	Clinical Information SESTATIONAL AGE: WKS / DO DATING METHOD: LMP CRL	AYS ON MM / DD / YYYY Other:
choose Either Test (NIPT or NIPT Plus) and All Operated Inchoose Either Test (NIPT or NIPT Plus) and All Operated Inchoose Either Test (NIPT or NIPT Plus) and All Operated Inchoose In	ptions That Apply Prenatal Plus Test chromosomes 21, 18, 13) Singleton options: leletions leletion, 4p- (Wolf-Hirschhorn), i-du-chat), 15q11.2 deletion (Prader- ngelman), 22q11.2 deletion (DiGeorge) chromosome aneuploides	Test Indications (Choose at least one): Advanced Matern Positive Serum So Abnormal Ultraso Hx suggestive of risk for the specifichromosome ane	nal Age	Clinical Information SESTATIONAL AGE: WKS / D. DATING METHOD: LMP CRL Date of Implantation	AYS ON MM/DD/YYYY Other:
chromosomes 21, 18, 13) Singleton Additional option: Presence of Chromosome aneuploidies option Presence of Chromosome Presence of Chromosome option Presence of Chromosome option	ptions That Apply Prenatal Plus Test chromosomes 21, 18, 13) Singleton options: leletions 49- (Wolf-Hirschhorn), i-du-chat), 15q11.2 deletion (Pradergelman), 22q11.2 deletion (DiGeorge)	Test Indications (Choose at least one): Advanced Matern Positive Serum So Abnormal Ultrass Hx suggestive of risk for the specif	nal Age creen cound increased fied uploidies ul anxiety	Clinical Information SESTATIONAL AGE: WKS / DO DATING METHOD: LMP	AYS ON MM / DD / YYYY Other:
Chromosomes 21, 18, 13 CR	ptions That Apply Prenatal Plus Test chromosomes 21, 18, 13) Singleton Options: leletions leletion, 4p- (Wolf-Hirschhorn), i-du-chat), 15q11.2 deletion (Pradergelman), 22q11.2 deletion (DiGeorge) chromosome aneuploidies (X, XXX, XXY, and XYY) Tomosomes (including sex osome aneuploidies (XXX, XXY, and XYY]) PATIENT CONSENT Serd/ID. I voluntarily consent to the coring provider. I further authorize my instruces from my insurer, I will remit said griself-pay" above, I acknowledge fina sation in the event of an invention resultie purpose of (diagnosis/research) (development of the volument of	Test Indications (Choose at least one): Advanced Materr Positive Serum So Abnormal Ultrass Hx suggestive of risk for the specifichromosome ane Low risk/materna Other: The reverse side for extende of payment to the Lab within ancial responsibility for all lab ing from research and development/quality control). I underetesting is required. The service of the	anal Age creen cound increased fied uploidies al anxiety A A A A A A A A A A A A A	Clinical Information SESTATIONAL AGE: WKS / D. DATING METHOD: LMP	Other: Cm ft in kgs lbs
Choose Either Test (NIPT or NIPT Plus) and All Operated Inchromosomes 21, 18, 13) Chromosomes 21, 18, 13) Chromosomes 21, 18, 13) Chromosomes 21, 18, 13) Chromosomes 21, 18, 13) Chromosome aneuploidies option Chromosome options Chromosome option	ptions That Apply Prenatal Plus Test chromosomes 21, 18, 13) Singleton Options: leletions leletion, 4p- (Wolf-Hirschhorn), i-du-chat), 15q11.2 deletion (Pradergelman), 22q11.2 deletion (DiGeorge) chromosome aneuploidies (X, XXX, XXY, and XYY) Tomosomes (including sex osome aneuploidies (XXX, XXY, and XYY]) PATIENT CONSENT Serd/ID. I voluntarily consent to the coring provider. I further authorize my instruces from my insurer, I will remit said griself-pay" above, I acknowledge fina sation in the event of an invention resultie purpose of (diagnosis/research) (development of the volument of	Test Indications (Choose at least one): Advanced Materr Positive Serum So Abnormal Ultrass Hx suggestive of risk for the specifichromosome ane Low risk/materna Other: The reverse side for extende of payment to the Lab within ancial responsibility for all lab ing from research and development/quality control). I underetesting is required. The service of the	anal Age creen cound increased fied uploidies al anxiety A A A A A A A A A A A A A	Clinical Information SESTATIONAL AGE: WKS / D. DATING METHOD: LMP	Other: Cm ft in kgs lbs

1508200300 (EX)



Pt. Name:





WHITE COPY: LAB YELLOW COPY: CLINIC PINK COPY: PATIENT Last Updated Oct

Pt. Name:

Date of Birth:

Molecular Genetics Informed Consent

Background on Testing

Molecular Risk Panels are designed to evaluate multiple genes that have been reported to be associated with an increased risk of developing one or more pathologic disease states. While LS is NOT diagnosing any specific condition, we do investigate for any changes in the specific genes that have been shown to increase the risk for molecular illness to develop, so as to help the patient and their physician make better informed choices, if necessary.

Potential limits of Molecular Risk Panels

- Med Labs partners do not look for all genetic causes of cancer. It is designed to study a set panel of genes known to cause certain inherited cancers.
- Med Labs partners do not provide any risk information for genes that we do not explicitly evaluate for.
- Med Labs partners require a minimum amount of sufficient DNA. Patients should not be concerned if the laboratory, or their physician, requests additional samples to complete the testing in a satisfactory manner.

Who may benefit from Molecular Risk Testing?

For benefits associated with each specific molecular assay kindly refer to our website: www.MedLabsUnlimited.com

Should my child (under 18 years old) have testing?

Genetic testing for children under 18 years old is not recommended except when an inherited condition is known to cause signs or symptoms that are recognized in childhood. You should talk with your health care provider and/or a genetic counselor about whether our testing or other genetic testing is right for your child.

How is testing performed?

Next generation sequencing (NGS), a technique that allows our group to interrogate a large amount of genetic information very quickly, enabling us to reliably identify very small changes in the implicated genes. Another technique is used to find any large missing or extra pieces of a gene. The clinical staff at the testing laboratory – which may include scientists, doctors, and genetic counselors – review any changes (called variants) found to determine if a variant might be benign (unlikely to cause harm) or pathogenic (known to be associated with an increased risk for genetic disease).

What can I learn from the report?

The report should ideally be interpreted in concert with a heath care professional qualified to assist you in understanding the results we provide, such as a certified genetic counselor. These professionals are trained to give unbiased and neutral details about your report information. You may learn if you have a higher potential risk to develop certain conditions compared to others in the general population. The results of this genetic test may change the way your healthcare provider chooses to manage your usual treatment. If you are found to have a variant (a change in the DNA sequence) that increases your risk to develop certain types of conditions, this information is important for your biologic (related by blood) relatives to know as well. They share some of the same DNA as you, which means that they might also have the same variant and may carry similar risk (either increased or decreased). If they are found to have the same variant, they may also benefit from multiple potential therapeutic options.

After you receive your results, you may have questions. Your healthcare provider can answer your questions and/or refer you to a genetic counselor for additional information.

What will happen to my specimen?

Specimens are stored according to all applicable federal, state and professional regulations. If no regulation applies, specimens will be stored no longer than 60 days from the collection date. The data generated by the test will be saved for at least one year after testing is completed. To continually improve the analysis process, your test results may be shared with a HIPAA-compliant public database in a way that is de-identified, so that no one else may know that the results came from you. The confidentiality of each specimen is of the utmost priority, and will be maintained in perpetuity, to the best of our ability.

Genetic Test Consent

- I understand the following and freely give my consent to have this genetic test performed.
- I have had an opportunity to read the information provided above and/or my healthcare provider has explained the risks, benefits, and limitations for the test ordered below. I am aware that genetic counseling is an option available to me both before and after testing.
- The test may provide me additional information about my inherited risk for diseases which may also have consequences for my blood relatives.
- The ability of genetic testing to provide risk information or a diagnosis varies with the type of test. I have been provided with information about LabSolutions' ability to detect changes in the genes tested, and/or my healthcare provider has discussed it with me in detail.
- I understand that I may have variants in genes that increase my risk of genetic disease that are not tested by LabSolutions at the time my test is performed.
- This test may not provide reliable information, regardless of the results for a number of reasons. Some of the reasons include: I) the need to test other family members; 2) no information known about the variant detected; 3) technical reasons.
- All test results are confidential and will be released only to the ordering healthcare provider or that healthcare provider's designated representative. I understand that in some states I may have to disclose this information to third parties, such as life, disability, or health insurers.
- Procedures to obtain blood specimens may have associated risks, such as bruising from blood collection.
- · An additional blood specimen may have to be obtained in the absence of results, or if the results are inconclusive.
- All specimens are coded with unique identifying information to assure quality and, to the extent humanly possible, prevent error.
- My specimen will be securely stored in case retesting is necessary. Specimens are stored according to applicable federal, state, and professional regulations. If no regulation applies, specimens will be stored no longer than 60 days from the collection date. At the end of that time, the specimen will be destroyed unless otherwise instructed below.